Outlook Therapeutics’ Lytenana Gains the CHMP’s Positive Opinion for the Treatment of Wet AMD
Shots:
-
Outlook’s Lytenava has received CHMP’s positive opinion to treat Wet AMD. If approved Lytenava expected to gain 10 yrs of market exclusivity in EU
-
The opinion was supported by 3 wet AMD clinical programs (NORSE ONE, NORSE TWO & NORSE THREE) assessing ONS-5010 along with retrospective bibliographic literature
-
Lytenava, an ophthalmic formulation of bevacizumab, is being developed as an intravitreal injection for treating wet AMD and other retinal diseases. It is an ophthalmic formulation of existing bevacizumab which has been off label used in wAMD globally
Ref: Outlook Therapeutics | Image: Outlook Therapeutics
Related News:- Outlook Therapeutics Reports EMA's Validation of MAA for ONS-5010 to Treat Wet AMD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
